We previously engineered Saccharomyces cerevisiae through CRISPR-Cas9 integration to produce Ply511, a bacteriophage endolysin active against L. monocytogenes, showing the potential of engineered yeast to produce endolysins for biocontrol. In this study, we extended this approach to the probiotic yeast S. boulardii and directly compared the two yeasts as secretion hosts for Ply511. Using a simulated human gastrointestinal environment, we evaluated their ability to retain endolysin activity and reduce L. monocytogenes levels.
New paper from the CEB- @uminho.bsky.social & APC
𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐨𝐟 𝐚𝐧 𝐚𝐧𝐭𝐢-𝐋𝐢𝐬𝐭𝐞𝐫𝐢𝐚 𝐞𝐧𝐝𝐨𝐥𝐲𝐬𝐢𝐧 𝐯𝐢𝐚 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬𝟗 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐞𝐝 𝐩𝐫𝐨𝐛𝐢𝐨𝐭𝐢𝐜 𝑺𝒂𝒄𝒄𝒉𝒂𝒓𝒐𝒎𝒚𝒄𝒆𝒔 𝒃𝒐𝒖𝒍𝒂𝒓𝒅𝒊𝒊
Appl Microbiol Biotechnol buff.ly/pDDfR3f
#CRISPRCas9
@ellen-murr.bsky.social @rioscolombo.bsky.social @colinhillucc.bsky.social